

ChromaDex to Present at the 7th Annual Liolios Gateway Conference on September 6, 2018

2018-08-29

IRVINE, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, has been invited to present at the **7th Annual Liolios Gateway Conference**, which is being held September 5-6, 2018 at the Four Seasons Hotel in San Francisco, CA.

ChromaDex management is scheduled to present on Thursday, September 6th at 1:30 p.m. Pacific time, with one-on-one meetings held throughout the day.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email gateway@liolios.com.

About the Gateway Conference

The 7th Annual Gateway Conference is an invite-only conference presented by Liolios, a full-service financial communications firm. Gateway was created to bring together the most compelling companies with the nation's top institutional investors and analysts. This year's event features approximately 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com. To receive updates and highlights from #LioliosGateway, make sure to follow us on **Twitter**, **LinkedIn** and **Facebook**.

About ChromaDex

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people

age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, **NIAGEN**[®] nicotinamide riboside, sold directly to consumers as **TRU NIAGEN**[®], is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER[®]. ChromaDex maintains a website at www.ChromaDex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

ChromaDex Investor Relations Contact:

Andrew Johnson, Director of Investor Relations

949-419-0288

andrewj@chromadex.com

ChromaDex Media Contact:

Alex Worsham, Director of Strategic Partnerships

949-648-3775

alexw@chromadex.com

ChromaDex